Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) operates as a synthetic biology platform company dedicated to making biology easier to engineer. The company maintains its headquarters in Boston and operates through two primary business segments: cell engineering and biosecurity. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Ginkgo Bioworks Holdings, Inc. does
In the company’s own words
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) operates as a synthetic biology platform company dedicated to making biology easier to engineer. The company maintains its headquarters in Boston and operates through two primary business segments: cell engineering and biosecurity.
The cell engineering segment provides biological research and development services and tools to government and commercial customers across medicine, agriculture, industrial biotechnology, and strategic government applications. Ginkgo's cell engineering platform combines proprietary automation technologies, including its Reconfigurable Automation Cart systems, with in-house software, machine learning, and generative AI models for cell programming. The company maintains massive databases of DNA sequences and functional performance data, along with reusable biological assets that enable faster and more predictable cell programming. Cell engineering service offerings span a spectrum from standardized tools and data generation services to customized end-to-end solutions. These include protein engineering and production for biopharmaceutical applications, genetic medicines development, small molecule and biologics services, crop nutrition and protection solutions, plant trait discovery, industrial biotechnology applications, and fermentation and scale-up capabilities. The company operates approximately 12,000 square feet of greenhouse facilities and maintains pilot plant capacity ranging from 5 to 3,000 liters.
The biosecurity segment provides services to government customers working to identify, monitor, prevent, and mitigate biological threats. This segment operates through two core offerings: Canopy, which generates high-value genomic data from strategically positioned monitoring nodes such as airports and border checkpoints, and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats worldwide. The biosecurity platform leverages genetic information as a critical data asset for next-generation threat detection and response.
Ginkgo generates revenue through service fees for research and development work, support services, and data generation programs, typically ranging from weeks to several years in duration. The company also structures value-sharing arrangements with customers through royalties, milestone payments, and equity interests aligned with commercialization success. The company website is www.ginkgobioworks.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1830214
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Ginkgo Bioworks Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Ginkgo Bioworks Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Ginkgo Bioworks Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Ginkgo Bioworks Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Ginkgo Bioworks Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”